AVTX Stock Analysis: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$18.19
0.36 (2.02%)
▲
5d:
+26.94%
30d:
+11.25%
90d:
+35.24%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: AVTX is 9.0% above its trading range ($16.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: AVTX is 9.0% above its trading range ($16.69). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $18.19, which is considered extended relative to its 30-day fair value range of $13.69 to $16.69.
Technical Outlook: Technically, AVTX is showing sideways momentum. The price is approaching resistance at $18.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.25 (+153.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AVTX is showing sideways momentum. The price is approaching resistance at $18.54. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $45.25 (+153.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.69 -
$16.69
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price extended above range (+9.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 153.8% below Wall St target ($45.25)
Trading Range Analysis
30-Day Trading Range
$13.69 -
$16.69
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.52
Resistance Level
$18.54
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.37
Wall Street Target
$45.25
(+153.8%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: June 24, 2026 12:46 PM ET
Data refreshes hourly during market hours. Next update: 1:46 PM
Data refreshes hourly during market hours. Next update: 1:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
